| The NSABP Study of Tamoxifen and Raloxifene (STAR) trial | 2009/01/01 | English | 66 |
| RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer | 2008/04/01 | English | 65 |
| Mathematical models of tumor cell proliferation: A review of the literature | 2018/10/22 | English | 65 |
| Novel therapeutic agents for osteosarcoma | 2009/04/01 | English | 65 |
| Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects | 2015/09/24 | English | 65 |
| Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders | 2011/03/01 | English | 65 |
| From tumor size andHER2status to systems oncology for very early breast cancer treatment | 2010/02/01 | English | 64 |
| Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer | 2002/04/01 | English | 64 |
| Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma | 2002/10/01 | English | 64 |
| Temozolomide: a milestone in neuro-oncology and beyond? | 2006/08/01 | English | 64 |
| AKT pathway in neuroblastoma and its therapeutic implication | 2008/05/01 | English | 63 |
| Bicalutamide (Casodex®) in the treatment of prostate cancer | 2004/02/01 | English | 63 |
| c-Myc as a therapeutic target in cancer | 2004/04/01 | English | 63 |
| Systemic and global toxicities of head and neck treatment | 2007/07/01 | English | 63 |
| Treatment of relapsed Wilms tumors: lessons learned | 2009/12/01 | English | 62 |
| Bortezomib in the front-line treatment of multiple myeloma | 2008/07/01 | English | 62 |
| The acetyl-CoA carboxylase enzyme: a target for cancer therapy? | 2015/05/15 | English | 62 |
| Targeting adenosine in cancer immunotherapy: a review of recent progress | 2017/04/27 | English | 61 |
| Aerobic glycolysis: a novel target in kidney cancer | 2013/06/01 | English | 61 |
| Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways | 2003/10/01 | English | 61 |
| Capmatinib for the treatment of non-small cell lung cancer | 2019/08/01 | English | 60 |
| Treatment of primary intraocular melanoma | 2006/04/01 | English | 59 |
| Role of chemotherapy in the management of soft tissue sarcomas | 2010/02/01 | English | 59 |
| TACE versus TAE as therapy for hepatocellular carcinoma | 2008/10/01 | English | 59 |
| Bevacizumab: overview of the literature | 2012/05/01 | English | 59 |
| New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy | 2015/04/11 | English | 59 |
| Key roles of the OPG–RANK–RANKL system in bone oncology | 2007/02/01 | English | 59 |
| The Wnt signaling pathway: implications for therapy in osteosarcoma | 2011/08/01 | English | 58 |
| Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors | 2017/12/06 | English | 57 |
| VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment | 2008/01/01 | English | 57 |